Nvidia CEO to Lilly CEO: You were running around the forest …
Jensen Huang, CEO of Nvidia and David Ricks, CEO of Eli Lilly, discussed their recently-announced partnership and the potential of GLP-1s at an event in San Francisco.
Nvidia Deepens Push Into Drug Discovery Via New Partnerships with Lilly, Thermo Fisher & More
At JPM, Nvidia unveiled partnerships with Eli Lilly, Thermo Fisher and others that show how the chipmaker is pushing its AI beyond models and into the core infrastructure of drug discovery and research labs. The moves highlight Nvidia’s ambitions to become a foundational technology provider for the pharma industry.
presented by
Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
Galapagos to Wind Down Cell Therapy Business After Search for a Buyer Comes Up Empty
Non-binding offers for Galapagos’s cell therapies assets came mostly from financial investors, and none offered sufficient terms or financing to support the business, the company said. Galapagos’s exit from cell therapy work will lead to site closures in Europe, China, and the U.S.
J.P. Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer
Enlaza Therapeutics’ drugs form covalent bonds that lock the therapy onto its target. With cancer as its initial focus, the startup contends its approach could offer safety and efficacy advantages compared to currently available targeted therapies.